title: Synergistic effects of injection of bone marrow cells into both portal vein and bone marrow on tolerance induction in transplantation of allogeneic pancreatic islets.
abstract: We have established a new method for allogeneic pancreatic islet (PI) transplantation: relatively low doses of irradiation followed by simultaneous transplantation of PIs and bone marrow cells (BMCs) via the portal vein (PV). In the present study, we have compared this method with intra-bone marrow (IBM)-bone marrow transplantation (BMT), and with a combination of both methods. Streptozotocin (STZ)-induced diabetic-recipient rats, Fischer 344 (F344, RT1A(l), RT1B(l)), were irradiated 1 day before transplantation. PIs of Brown Norway rats (BN, RT1A(n), RT1B(n)) were transplanted into the liver of the diabetic F344 rats via the PV. BMCs from BN rats were injected into the recipients' bone marrow (IBM), PV or intravenously (IV) or by a simultaneous combination of PV plus IBM (PV+IBM). We compared graft survival among the groups of '9 Gy+IBM'(10/10 accepted), '9 Gy+PV'(7/10 accepted), '9 Gy+IV'(0/7 accepted), '9 Gy+PV+IBM'(8/8 accepted), '8.5 Gy+IBM'(4/9 accepted), '8.5 Gy+PV'(0/7 accepted), '8.5 Gy+IV'(0/7 accepted), '8.5 Gy+PV+IBM'(9/12 accepted), '8 Gy+IBM'(2/10 accepted) and '8 Gy+PV+IBM'(2/8 accepted). As we reported previously, PV-BMT is more effective in inducing the acceptance of allogeneic PIs than IV-BMT. However, IBM-BMT requires less pretreatment than PV-BMT. (PV+IBM)-BMT was found to be the most effective in inducing the acceptance of allogeneic PIs. These results suggest that allogeneic PI-transplantation in conjunction with (PV+IBM)-BMT could become a viable strategy.
authors.affiliation: First Department of Pathology, Kansai Medical University, 10-15 Fumizono-cho, Moriguchi City, Osaka 570-8506, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Ikebukuro
authors.forename: Y
authors.initials: Y
authors.lastname: Adachi
authors.forename: Y
authors.initials: Y
authors.lastname: Suzuki
authors.forename: M
authors.initials: M
authors.lastname: Iwasaki
authors.forename: K
authors.initials: K
authors.lastname: Nakano
authors.forename: Y
authors.initials: Y
authors.lastname: Koike
authors.forename: H
authors.initials: H
authors.lastname: Mukaide
authors.forename: Y
authors.initials: Y
authors.lastname: Yamada
authors.forename: S
authors.initials: S
authors.lastname: Fujimoto
authors.forename: Y
authors.initials: Y
authors.lastname: Seino
authors.forename: H
authors.initials: H
authors.lastname: Oyaizu
authors.forename: A
authors.initials: A
authors.lastname: Shigematsu
authors.forename: N
authors.initials: N
authors.lastname: Kiriyama
authors.forename: Y
authors.initials: Y
authors.lastname: Hamada
authors.forename: Y
authors.initials: Y
authors.lastname: Kamiyama
authors.forename: S
authors.initials: S
authors.lastname: Ikehara
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D016026:Bone Marrow Transplantation / Q000379:methods*; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000276:immunology / Q000628:therapy; D005260:Female; D006085:Graft Survival; D007108:Immune Tolerance; D016381:Islets of Langerhans Transplantation / Q000379:methods* / Q000473:pathology / Q000502:physiology; D008297:Male; D011169:Portal Vein; D051381:Rats; D011912:Rats, Inbred ACI; D011914:Rats, Inbred BN; D011916:Rats, Inbred F344; D014184:Transplantation, Homologous
chemical_list: D001786:Blood Glucose